Gut microbiota interventions in type 2 diabetes mellitus: An umbrella review of glycemic indices

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2024-08-01 DOI:10.1016/j.dsx.2024.103110

{"title":"Gut microbiota interventions in type 2 diabetes mellitus: An umbrella review of glycemic indices","authors":"","doi":"10.1016/j.dsx.2024.103110","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>We aimed to explore how probiotics, prebiotics, or synbiotics impact glycemic indices in patients with diabetes mellitus.</p></div><div><h3>Method</h3><p>A comprehensive search was conducted on PubMed, Scopus, and Web of Science from inception up to April 2023. The random-effects model was employed for the study analysis. Furthermore, sensitivity and subgroup analyses were conducted to investigate potential sources of heterogeneity. AMSTAR2 checklist was used to determine the quality of studies. Comprehensive meta-analysis version 3 was used for the study analysis.</p></div><div><h3>Result</h3><p>A total of 31 studies were included in the final analysis. Based on the results of the meta-analysis, gut microbial therapy could significantly decrease serum fasting blood glucose levels in patients with type 2 diabetes mellitus (effect size: −0.211; 95 % CI: −0.257, −0.164; P < 0.001). Additionally, significant associations were also found between gut microbial therapy and improved serum levels of fasting insulin, glycated hemoglobin, and homeostatic model assessment for insulin resistance (effect size: −0.087; 95 % confidence interval: −0.120, −0.053; P < 0.001; effect size: −0.166; 95 % confidence interval: −0.200, −0.132; P < 0.001; effect size: −0.230; 95 % confidence interval: −0.288, −0.172; P < 0.001, respectively).</p></div><div><h3>Conclusion</h3><p>Our results revealed promising effects of gut microbiota modulation on glycemic profile of patients with type 2 diabetes mellitus. The use of these agents as additional treatments can be considered.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1871402124001711","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background

We aimed to explore how probiotics, prebiotics, or synbiotics impact glycemic indices in patients with diabetes mellitus.

Method

A comprehensive search was conducted on PubMed, Scopus, and Web of Science from inception up to April 2023. The random-effects model was employed for the study analysis. Furthermore, sensitivity and subgroup analyses were conducted to investigate potential sources of heterogeneity. AMSTAR2 checklist was used to determine the quality of studies. Comprehensive meta-analysis version 3 was used for the study analysis.

Result

A total of 31 studies were included in the final analysis. Based on the results of the meta-analysis, gut microbial therapy could significantly decrease serum fasting blood glucose levels in patients with type 2 diabetes mellitus (effect size: −0.211; 95 % CI: −0.257, −0.164; P < 0.001). Additionally, significant associations were also found between gut microbial therapy and improved serum levels of fasting insulin, glycated hemoglobin, and homeostatic model assessment for insulin resistance (effect size: −0.087; 95 % confidence interval: −0.120, −0.053; P < 0.001; effect size: −0.166; 95 % confidence interval: −0.200, −0.132; P < 0.001; effect size: −0.230; 95 % confidence interval: −0.288, −0.172; P < 0.001, respectively).

Conclusion

Our results revealed promising effects of gut microbiota modulation on glycemic profile of patients with type 2 diabetes mellitus. The use of these agents as additional treatments can be considered.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

2型糖尿病的肠道微生物群干预：血糖指数综述

背景我们旨在探讨益生菌、益生元或合成益生菌如何影响糖尿病患者的血糖指数。方法在PubMed、Scopus和Web of Science上进行了从开始到2023年4月的全面搜索。研究分析采用随机效应模型。此外，还进行了敏感性分析和亚组分析，以调查潜在的异质性来源。采用 AMSTAR2 核对表确定研究质量。结果共有 31 项研究被纳入最终分析。根据荟萃分析结果，肠道微生物疗法可显著降低 2 型糖尿病患者的血清空腹血糖水平（效应大小：-0.211；95 % CI：-0.257，-0.164；P <；0.001）。此外，研究还发现，肠道微生物疗法与空腹胰岛素、糖化血红蛋白和胰岛素抵抗稳态模型评估的血清水平改善之间存在明显关联（效应大小：-0.087；95 % CI：-0.164；P <；0.001）：-0.087；95% 置信区间：-0.120，-0.053；P <；0.001；效应大小：-0.166；95 % 置信区间：-0.053；P <；0.001）：效应大小：-0.166；95 % 置信区间：-0.200，-0.053；P < 0.001-0.166；95 % 置信区间：-0.200，-0.132；P <；0.001；效应大小：-0.230；95 % 置信区间：-结论我们的研究结果表明，调节肠道微生物群对 2 型糖尿病患者的血糖状况具有良好的影响。可以考虑使用这些制剂作为额外的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Diabetes & Metabolic Syndrome-Clinical Research & Reviews ENDOCRINOLOGY & METABOLISM-

CiteScore

22.90

自引率

2.00%

发文量

248

审稿时长

51 days

期刊介绍： Diabetes and Metabolic Syndrome: Clinical Research and Reviews is the official journal of DiabetesIndia. It aims to provide a global platform for healthcare professionals, diabetes educators, and other stakeholders to submit their research on diabetes care. Types of Publications: Diabetes and Metabolic Syndrome: Clinical Research and Reviews publishes peer-reviewed original articles, reviews, short communications, case reports, letters to the Editor, and expert comments. Reviews and mini-reviews are particularly welcomed for areas within endocrinology undergoing rapid changes.